# Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

> **NCT04821765** · PHASE2 · COMPLETED · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 35 (actual)

## Conditions studied

- Esophagus Cancer
- Chemoradiotherapy
- Oligometastatic Disease
- Immunotherapy

## Interventions

- **DRUG:** PD-1 antibody
- **RADIATION:** Chemoradiation
- **DRUG:** Albumin-Bound Paclitaxel
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT04821765
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04821765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04821765, "Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04821765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*